How Collaboration in Pharmatech Industries Can Save Lives | EVAMAX Group

The pharmaceutical industry has experienced an abundance of change and adaptation as of late due to recent advancements and technological growth. The capabilities of current healthcare technologies are far more advanced than what they were 5-10 years ago. 

That being said, there is still always room for improvement and strategies to mitigate inefficiencies.  

As of late, those in the pharmaceutical and related industries have been focusing on collaboration to overcome certain obstacles and expand our current knowledge. Whether this is through partnerships or collaborative research, the collective idea of joining together to improve processes has many benefits. 

If you are a company in the midst of an industry transformation or partaking in activities seeking technological advancement, EVAMAX can help you discover the innovation grants and benefits you could be eligible for. 

As previously stated, technological growth and advancement have had a huge impact on the pharmaceutical and healthcare industries. We are now capable of completing tasks and performing operations that were not possible years ago. Through collaboration, we can enhance and expedite this process in order to be more successful in our findings.  

Related: VR in the ER: Benefits of Virtual Reality in the Healthcare Industry

For example, Pfizer has partnered with IBM to predict new potential drug targets. Through this partnership, Pfizer has gathered research that can lead to new treatments such as new cancer therapies.

When associated with technology, partnerships can develop products, personalize medicine, expand research capabilities, and so much more. Collaboration amongst those in the pharmatech industries will avoid wasted expenses through streamlining processes and techniques to be as efficient as possible. 

Related: Cloud and Clear: Hospitals Transitioning to Cloud Computing Systems

In addition, collaboration in the pharmatech industries will assist the research, treatment and mitigation of complex diseases, such as Alzheimer’s and diabetes. Issues arising around such complex diseases are only increasing as the number of victims is expected to continue growing. 

As an example, the number of people affected by dementia is expected to more than triple in 30 years time. To combat this, the prime minister of the United Kingdom, where there are 500,000+ people are affected by dementia, has made efforts to collaborate with industry experts to work towards a solution.  

Related: CSSP Collaborates with Carleton University in $2 Million e-Health Systems

A program called the Dementia Discovery Fund was launched to gather funding from private, public, and philanthropic sectors. The purpose of this was to pool their expertise together in order to expedite the process of identifying a treatment. There are similar funds and partnerships around the world that pertain to different aspects of the pharmatech industry. The information acquired through collaboration can lead to research targets and ultimately new treatments. 

Related: Grants for Biotech, Lifesciences and Medical Technology

All in all, collaboration is key in accommodating the constant adaptations within the pharmatech industries. Even health care providers and other pharmaceutical companies are on board, collaborating with patients in order to identify better treatment outcomes.

The key to solving the issues we face is to work together in order to compile expertise from a broad range of skillsets and knowledge.  

Contact EVAMAX today for a no-obligation consultation regarding available grants for the Pharmatech and Innovation-driven industries. 



The Health Technologies Fund (HTF) is a program of the Government of Ontario, developed by the Office of the Chief Health Innovation Strategist (OCHIS), administered by the Ontario Centres of Excellence.  It supports the development of made-in-Ontario health technologies. It provides grants to businesses and research organizations seeking to improve the quality and deliverability of healthcare in the province by testing and adopting new technologies.(Source:

The HTF is currently available to healthcare providers, technology developers, and academic institutions in the province of Ontario.

Created by the Ontario local government, the HTF is developed by the Office of the Chief Health Innovation Strategist and administered by the Ontario Centres of Excellence. Its main objective is to forge partnerships among publicly funded health service providers (HSPs), patients, academia and industry in streamlining the evaluation, procurement, and adoption of healthcare technologies in the Ontario health system. With the theme of “Better Care Closer to Home,” the HTF is primarily focused on improving the deliverability of healthcare services to patients in the province.

Key Areas of Focus

The HTF has two main drives:

  • Pre-Market Evaluation:

Projects under this area deal with the implementation of validated technology in a healthcare setting through proper evaluation and assessment practices, and acquisition of evidence-based data on the cost-effectiveness of the technology as well as its perceived impact to the healthcare industry. This is to support procurement programs and support wide-scale procurement activities and programs in the future.

Projects under the pre-market evaluation stream may include identification of changes in the clinical workflow, collection of data & generating evidence to support procurement goals, and creating plans for adopting a validated technology.

Clinical trials that determine a technology’s efficacy are excluded as well as activities that are not based in the province of Ontario.

  • Early Adoption:

Projects under this area support validated market-ready technologies that have been successfully implemented in one or more healthcare settings. These projects must involve a HIT collaborating to perform an additional implementation (and preferably multiple implementations) of the technology (in one or more healthcare settings) in order to evaluate the technology across multiple implementations, to generate further evidence to support value-based procurement and wide-scale adoption plan.

Projects under the early adoption stream may include streamlining and identifying changes in clinical workflow, to successfully integrate the technology, knowledge translation and user training, collecting evidence for future procurement activities, and creating procurement and adoption plans for healthcare providers.

Similar to projects under the pre-market evaluation, clinical trials that determine a technology’s efficacy and activities that are not based in the province of Ontario are excluded from the program.

Projects under both categories must align with the theme of Better Care Closer to Home and the technologies must have obtained required regulatory approvals and received initial user feedback.

Who Qualifies:

The HTF is currently accepting applications from Health Innovation Teams (HITs), which comprises the following members:

  • Applicant

One or more Providers of publicly-funded Health Services Provider. Eligible health care system applicants include (but are not limited to) family health teams, community care providers, long-term care homes, and hospitals.

  • Technology partner

This includes Ontario-based for-profit health technology businesses that provide solutions and conduct research innovations that are in line with the HTF’s main drive.

Partners may be of any size or stage (start-up, small- to medium-sized enterprise, and multinational enterprise) with a research and development, and/or manufacturing presence in Ontario.

  • Third-Party Evaluation Provider

 Ontario-based evaluation team with expertise in technology adoption and diffusion, design and implementation, and health economics. The evaluation component of the project should support the development of a plan to support wider-scale procurement and/or adoption of the technology in Ontario.

  • Other contributors

It is strongly recommended that partners such as community-based associations and advocacy groups are included in addition to Local Health Integration Network (LHIN) to provide sector expertise to ensure project development and implementation meets sector and local needs.


Pre-Market Evaluation projects Up to 50 percent of the eligible project cash costs up to a maximum amount of $500,000 for a term of up to 24 months.

Early Adoption projects Up to 50 percent of the eligible project cash costs up to a maximum amount of $1,000,000 for a term of up to 24 months.

Eligible Expenditures:

Actual costs directly attributable to and necessary for the completion of the project and are not wholly or partially for another purpose.

  • One-time costs, directly attributable to implementation of the project;
  • Retroactive Expenses: OCE will acknowledge expenses after the approval date.
  • Founder’s Salary: For a Start-up company, the maximum allowable compensation of $5,000 per month
  • Cost of utilization/depreciation of Capital items i.e. equipment, testing tools, and instruments used for the project.


  • Interested HITs may submit their expressions of interest (EOI) until May 9, 2018.
  • Invitation to Submit a Full Application: July 2018
  • Full Application submission deadline: August 16, 2018

Application process

Interested applicants may submit their EOIs to the OCE. After a thorough assessment, the OCE and OCHIS will contact candidates for the program to submit a full application.


For assistance in preparing your submission and to position your application for approval contact EVAMAX Group to help you with the process.



NSERC Engage

CRD Grants provide innovative companies in Canada access to the academic resources available at Canadian universities and colleges. These grants are intended to motivate companies to form partnerships with the academic community in Canada and support long-term research and development activities aimed at solving a specific problem for the company such as the development of a new product or improvement to an existing process.


Funding Type:

CRD Grants offers companies up to 50% of eligible project expenses to a maximum of $200,000 per year for five years to a project maximum of $1 million to support the joint collaboration between the academic institution and the company and offset project costs.


Eligible Activities:

  • The project must generate new knowledge or apply existing knowledge in an innovative way to solve a company-specific problem
  • This problem must relate directly to the company’s products and services
  • The company must be able to further develop the results after the project is completed.
  • The project must have short-term to medium-term objectives or discrete phases in a longer-range research program
  • Have detailed budget and project plan


Applications are evaluated mainly against the following criteria:

  • Technical merit
  • Competence of research team
  • Training opportunities
  • Industrial relevance and potential for innovation impact
  • Benefit to Canada
  • University support
  • Budget


The NSERC CRD program reimburses project costs including:

  • Labour
  • Research equipment
  • Laboratory/ research facility usage fees
  • Materials and supplies
  • Travel
  • Administrative costs
  • Publication costs
  • Workshops
  • Certain project management related expenses for complex projects up to a maximum of 10% of the total direct costs


Who can apply?

  • Established businesses, start-ups, and industry associations operating in Canada
  • Demonstrate clear intention of completing the project
  • Contribute at least 50% of research project costs
  • Collaborate on all stages of the project (from proposal to project completion)
  • Regularly interact with academic personnel



Applications have an open-intake and will be processed on a first-come, first-served basis, subject to the availability of funding. The company initiates the collaboration process by creating a detailed research proposal to be taken to an academic institution to find a professor with the capabilities to support the project.

Once a match has been made between the school and company, the professor and/or research institution initiates the NSERC CRD grant application. Decisions are usually made within three months or up to six months for large/complex applications.


For assistance in preparing your submission and to position your application for approval contact EVAMAX Group to help you with the process. You may also email us at or call 1-877-711-7733